Although immunotherapy agents were not directly tested in this study, integrating CTC profiling with PD-L1 expression, tumor mutational burden, or immune gene signatures may extend this platform to predict response to immune checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.